MedTrace Logo

Booster Vaccination Study With a Pneumococcal Vaccine in Children Primed With the Same Vaccine

NCT00911144 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2018-09-20

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the reactogenicity, safety and immunogenicity of a booster (fourth) dose of pneumococcal vaccine GSK1024850A when co-administered with Hiberix at 12-18 months of age, in children primed with the same vaccines in primary study NCT00680914.

Conditions

  • Infections, Streptococcal

Interventions

BIOLOGICAL

GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)

Intramuscular injection, administered as a single dose

BIOLOGICAL

Wyeth-Lederle's Prevenar™

Intramuscular injection, administered as a single dose

BIOLOGICAL

GSK Biologicals' Hiberix™

Intramuscular injection, administered as a single dose

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Months
Max Age
18 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-11
Primary Completion
2010-01-11
Completion
2010-01-11

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00911144 on ClinicalTrials.gov